AIVITA Biomedical Closes $25 Million Financing Round
IRVINE, Calif., Dec. 29, 2020 -- (Healthcare Sales & Marketing Network) -- AIVITA Biomedical, Inc., a private biotechnology company developing personalized vaccines for the treatment of cancer and prevention of COVID-19, has closed its Series B-2 financin... Biopharmaceuticals, Oncology, Venture Capital AIVITA Biomedical, cancer vaccine, immunotherapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Cancer Vaccines | COVID-19 | Immunotherapy | Marketing | Pharmaceuticals | Vaccines | Venture Capital